Olof Andries BLOKZIJL,Johan Erik Simon FREDRIKSSON
申请号：
US16333552
公开号：
US20190256592A1
申请日:
2017.09.15
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention providesabinding agent capable of binding to the extracellular domain of CLPTM1 for use in the treatment or prevention of a condition which is responsive to, or benefits from, (i) immunosuppression, (ii) the reduction or reversal of one or more pro-inflammatory cytokines or the induction of an anti-inflammatory cytokine), (iii) an increase in insulin sensitivity, or (iv) therapy with GDF15 and/or TGF-β and/or IFNβ, wherein said binding agent has an EC 50 value of 1 μg/ml or less when determined by measuring binding to membrane-permeabilised O-876 cells expressing native CLPTM1 by flow cytometry, and wherein said binding agent is not a natural ligand for CLPTM.
